Sonidegib

Sonidegib (INN) or erismodegib (USAN), also known as LDE225, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis. It has been investigated as a potential treatment for:
 * Pancreatic cancer
 * Breast cancer
 * Basal cell carcinoma of the skin
 * Small cell lung cancer
 * Medulloblastoma
 * Advanced solid tumours (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)
 * Acute leukaemia
 * Chronic myeloid leukaemia
 * Myelofibrosis and essential thrombocythaemia

It has demonstrated significant efficacy against melanoma in vitro and in vivo. It also demonstrated efficacy in a mouse model of pancreatic cancer.